Skip to main content
. 2018 Jun 14;103(11):1853–1861. doi: 10.3324/haematol.2018.191536

Figure 5.

Figure 5.

Impact of Eastern Cooperative Oncology Group performance status, Medical Research Council classification and IDH1 mutations on overall survival. Overall survival in patients with an ECOG performance status of 0-2, favorable or intermediate MRC category and IDH1-wildtype compared to patients with an ECOG performance status of 3–4 or MRC adverse category or IDH1 mutation.